Continuous manufacturing of pharmaceuticals replaces discrete batch steps with one integrated line that never stops feeding. Nine oral solid dosage products have been approved on that basis since 2015, across sixteen approval numbers and four regulatory agencies. In each case, continuous manufacturing regulatory approval came down to the paperwork around the process: batch definition, process validation, technology transfer, model validation and material traceability.
What continuous manufacturing of pharmaceuticals changes
A batch line charges material into a vessel, processes it, empties it and tests it. A continuous line keeps material moving through linked unit operations at a steady rate and measures quality while the material is still in motion. Nearly every regulatory difference follows from that one shift: how you scale, how you define a batch, how you trace material, how you release product.
The gains show up consistently in the published cases. Design is more flexible. Runs are shorter. You scale by running longer rather than buying bigger vessels. Inline instruments produce far denser data than pulling samples from a finished lot ever could. Quality by design and process analytical technology matured alongside each other, which is what turned the transition from a good idea into something you could actually file.
The friction sits somewhere else entirely. Batch definition, control strategy, traceability, what to do with material that fails, and the release strategy all have to be argued from scratch once a process has no clear beginning and no clear end.
| Dimension | Batch manufacturing | Continuous manufacturing |
| Material flow | Discrete lots, charged and discharged | Continuous feed held near steady state |
| How scale is increased | Larger vessels and larger lots | Longer run time at a fixed rate |
| Where quality is demonstrated | Finished product testing dominates | In process measurement dominates |
| Batch definition | A fixed mass per lot | By mass, by time, or a defined range |
| Traceability | Lot numbers of input materials | Time stamps and product keys |
| Release | Finished product specification | Real time release where justified |
The sixteen approvals at a glance
Oral solid dosage forms carried continuous manufacturing into commercial production, and the record shows it. The counts below run from the first approval through the end of 2021.
| Metric | Figure |
| Year of first approval | 2015 |
| Products approved | 9 |
| Separate approval numbers | 16 |
| Approvals at the FDA | 7 |
| Approvals at the EMA | 6 |
| Approvals at the MHRA | 1 |
| Approvals at the PMDA | 2 |
| Sponsoring groups | 4 |
| Distinct process types | 3 |
Three process routes account for every named product: continuous wet granulation, continuous dry granulation and continuous direct compression. Four sponsoring groups account for all of them, holding three, three, two and one product respectively.
Seven of the nine products can be examined individually. The other two are counted in the totals but there is not enough described detail to treat them product by product here.
| Product | Sponsor | First approval | Therapeutic area | Process route | Platform note |
| Orkambi | Vertex | 2015, FDA | Cystic fibrosis | Continuous wet granulation | Fully integrated line, three manufacturing sites |
| Prezista | Janssen | 2016, FDA | HIV | Continuous direct compression | First post approval change from batch to continuous |
| Verzenio | Eli Lilly | 2017, FDA | Oncology, CDK4/6 inhibitor | Continuous direct compression | Two replicated, identical lines |
| Daurismo | Pfizer | 2018, FDA | Acute myeloid leukemia | Continuous direct compression | Portable modular platform |
| Symdeko | Vertex | 2018, FDA | Cystic fibrosis | Continuous wet granulation | Two strengths continuous, two strengths batch |
| Trikafta | Vertex | 2019, FDA | Cystic fibrosis | Continuous wet granulation | Development and launch platform |
| Abrocitinib | Pfizer | 2020, MHRA | Atopic dermatitis | Continuous direct compression | Same modular platform as Daurismo |
The therapeutic spread is narrow, and that is the point. Cystic fibrosis, HIV, oncology, acute myeloid leukemia and atopic dermatitis account for every named product, and three of the seven belong to a single sponsor. Continuous manufacturing never spread evenly through the industry. It was taken up by a handful of groups who had the engineering bench and the portfolio economics to justify it.
Orkambi: the first continuous manufacturing approval
Orkambi was approved in July 2015 for cystic fibrosis and became the first product anywhere to be cleared on a continuous process. The line sits on a fully integrated platform from an equipment supplier, and its defining feature is that raw powder is fed into the system through an intermediate vessel, after which dry granulation, wet granulation and coating all run without interruption.
The process runs in two stages. First, crystalline active substance is dissolved with a polymer and a surfactant in solvent, then spray dried into a powder. A second drying step pulls residual solvent down to an acceptable limit and leaves a free flowing, compressible powder, the spray dried dispersion. Second, tablet production finishes in seven steps: intragranular blending, twin screw wet granulation, fluid bed drying and milling, extragranular blending, compression, film coating and packaging.
The instructive part is not the chemistry. It is that the sponsor built three manufacturing sites at three different levels of automation maturity, all on the same wet granulation route.
| Site | Configuration | Distinguishing capability |
| Site 1 | Twin screw granulator fed by a batch blender, separate batch fluid bed dryer | Partly decoupled, batch drying retained |
| Site 2 | Continuous line from granulation through compression, premixing and film coating run in batch mode | Continuous core, batch at the edges |
| Site 3 | Single integrated system from individual component input to finished film coated tablet | Continuous throughout, supports real time release |
Site 3 is the one to study if you are planning a submission. It runs continuously from the individual material inputs all the way to a finished film coated tablet, and it supports real time release testing. Same product, same chemical route, three materially different levels of integration, all approved. What regulators assessed was the control strategy, not the equipment list.
Prezista: the first post approval change to continuous manufacturing
Prezista was approved in April 2016 as a protease inhibitor antiviral for HIV, produced on an integrated continuous direct compression platform. Powder is conveyed into the system under vacuum, then blended, compressed and coated. Nothing stops, nothing is batched, and process analytical technology controls the whole sequence.
This one deserves separate treatment because it was the first time a marketed product changed from batch manufacturing to continuous manufacturing. The sponsor gave three reasons for taking that route. Direct compression is mechanically simple. The product was mature and its process was stable. The indication served a large patient population, so a second process route could be paid for commercially.
Copy that reasoning. An already marketed product is not a good conversion candidate because it skips the registration burden. It is a good candidate because the existing batch data set becomes part of the evidence for the continuous design space.
The supplemental application addressed the concerns a reviewer is likely to raise, covering line management, equipment integration, the process control model and prior communication with the agency. Work with an academic engineering group integrated single equipment components from different vendors at the mechanical and electronic control level. Each unit, from feeders to blenders, was then characterised to pin down its mathematical model, its terminology, its residence time distribution, how the material behaved and how it moved from inlet to outlet. The submission concentrated on proving the level of line control and the ability to assure quality continuously. The agency had engaged with the sponsor on the plan and the models beforehand, gave feedback, and the sponsor adjusted.
Verzenio: designing for replication
Verzenio was approved in September 2017 as an oral CDK4/6 inhibitor, produced on a semi integrated continuous direct compression platform combining accurate powder feeding, blending and compression. A purpose built lift system supports the main process flow and is easy to clean and to reconfigure.
Its real contribution to the field was proving that a continuous line can be copied. In 2014 the sponsor built a GMP compliant continuous line inside an existing oral solid dosage facility in the United States. In 2015 it replicated that line inside a second existing facility in Puerto Rico. Both lines use continuous direct compression with the same equipment, the same layout, the same process analytical technology instruments and the same automation scheme.
Replication is what makes technology transfer tractable. Because the two sites are functionally identical, the transfer package does not have to argue that two different processes are equivalent. It only has to confirm that the second line was built and qualified as specified. That also compresses the time between development and commercial supply and removes the cost of a separate scale up exercise, which is why a modular approach starts to look attractive for a portfolio rather than for one product.
Daurismo and Abrocitinib: portable modular platforms
Daurismo was approved in November 2018 for acute myeloid leukemia with orphan drug and priority review designations. The tablet core is produced by direct compression on a platform described as portable, continuous, miniature and modular, developed with a facility construction partner and an equipment supplier. The unit was prefabricated and installed inside an existing warehouse rather than a purpose built plant, and the design is explicitly meant to be dismantled and moved.
The process covers three continuous steps: continuous feeding, continuous blending and compression on a conventional rotary tablet press. The final film coating runs as a batch operation on standard equipment. A continuously produced core followed by a batch coating step is worth naming as its own category. It is a hybrid, and the submission has to describe it as one instead of pretending the whole line is continuous.
A second product, the oral JAK1 inhibitor Abrocitinib, was approved in the UK in 2020 for atopic dermatitis on the same portable modular platform. Two molecules, two agencies, one platform. When the equipment is transportable and the automation scheme is fixed, the regulatory argument travels with the platform instead of being rebuilt for every product.
The European submission for Daurismo, filed in 2019, shows what a process risk assessment has to contain. It came in three parts.
Quality risk assessment. Development focused on the product and quality attributes defined in the quality target product profile, so that quality, efficacy, stability and safety were fixed in the specification. Risk based evaluation, combined with laboratory work, computational models and manufacturing experience, built a complete understanding of how formulation and process conditions affect those attributes.
Multivariate experimental design. A planned multivariate study examined how the defined process parameter ranges affect product quality attributes. For continuous feeding, experiments showed that the gravimetric feeder could deliver at the target mass flow rate with only small instantaneous fluctuation around the overall target. Batches of active substance and excipients were included so that variation in material properties could be tested against feeder performance, and every feeder was monitored continuously and controlled to the target feed rate. For continuous blending, a risk assessment guided the experimental work and established the residence time distribution, alongside three representative step change experiments used to infer the dynamics of the whole process system.
Process analytical technology. The line used an in house near infrared process control system able to monitor and reject non conforming material in real time. Because the near infrared guidance in force at the time required a validated model, and because a model can be unavailable for a period, the sponsor wrote a contingency plan: stratified sampling of tablet cores with offline testing by a high performance liquid chromatography reference method. Layered control and alarms detect shifts in core content, and out of specification material is rejected.
Symdeko and Trikafta: one platform, three products
Symdeko was approved in 2018 for cystic fibrosis, and its filing is the clearest example of a split strategy. The 50 mg and 75 mg strengths stayed on the original batch process. The 100 mg and 150 mg strengths moved to the continuous process, sharing the platform already used for Orkambi.
The justification is simple and worth repeating. The continuous process for the higher strengths follows the same principle as the batch process for the lower strengths, because the unit operations and the materials are identical. Where the material attributes of the spray dried dispersion interact with process parameters, the agency also reviewed model verification data to confirm that the process model predicted accurately.
Trikafta, approved in October 2019 and again for cystic fibrosis, was developed and launched on a continuous platform. The clinical supplies were originally made by a non continuous process, but both non continuous and continuous processes produced material for the pivotal trials, and both used exactly the same equipment. Note the shape of that argument. Comparability here rested on trial material, not only on developmental data.
A process control system runs the platform. It displays the running unit operations, the status of in process and critical process parameters, process trends and alarms. Material is tracked by a product key. When an in process control result falls outside the acceptable range, material carrying the affected key is diverted out of the process, using a method validated for that purpose.
What the ICH Q13 continuous manufacturing guidance changed
The guidance arrived in stages. Harmonisation work on continuous manufacturing of drug substances and drug products started in 2018, with the aim of aligning how different regions evaluate and inspect continuous processes. It reached a second consultation stage in July 2021 and has since been adopted across member regions. The FDA had already put out its own draft guidance in February 2019.
What that buys an applicant is predictability. FDA continuous manufacturing guidance and EMA continuous manufacturing guidance have converged on the same questions: batch definition, control strategy, process models, process validation and material traceability turn up in every serious review, and they turn up whether you are filing a new product or a change to a marketed one.
The seven questions that decide a continuous manufacturing review
Review experience across these products converges on a small set of recurring questions. They turn up whether the submission is for a new product or for a change to an existing one.
| Review question | What the reviewer is really asking | What convincing evidence looks like |
| Batch definition | Can you state what one batch is, and defend the range you claim? | A mass based definition with a fixed production rate |
| Process validation | Do development, clinical and commercial data together support the design space? | Pooled development, clinical and commercial scale data |
| Technology transfer | Are the two lines genuinely the same, not merely similar? | Equipment qualification plus site comparability data |
| Cleaning validation | Can this equipment be cleaned and have parts changed easily? | Same agents, procedures, methods and protocol as batch |
| Process monitoring and control | What happens when the analyzer fails or is unavailable? | Redundant control plus a documented contingency plan |
| PAT robustness | Has the model been validated, and will it be maintained? | Multivariate model validation and a lifecycle plan |
| Material traceability | Can you find and remove everything made during a bad interval? | Time stamps or product keys linking material to finished units |
Everything else in the submission supports one of those seven.
What the CTD has to say differently
A continuous manufacturing submission goes into the same Common Technical Document as any other, but several sections of 3.2.S and 3.2.P carry content that batch filings usually leave thin.
| CTD location | Continuous manufacturing content |
| Pharmaceutical development (3.2.P.2) | Model development and justification, and the control strategy |
| Description of manufacturing process and process controls (3.2.P.3.2) | Batch definition, and an overview of the model within the control strategy |
| Control of critical steps and intermediates (3.2.P.3.3) | Model validation data and the maintenance plan |
| Specification and analytical procedures (3.2.P.5) | Method and acceptance criteria where real time release is used |
| Justification of specification (3.2.P.5.6) | Analytical control strategy summary where process analytical technology is used |
Three entries in that table get underestimated most often: the batch definition rationale, the model validation and maintenance plan, and the analytical control strategy summary. Each one asks you to justify a design decision instead of reporting a result.
Batch definition in continuous manufacturing: time, mass, or a range
Existing guidance allows a batch to be defined by production time or by material mass, and it allows batch size to be expressed as a range. If nothing else changes, you increase batch size by running for longer, and changes inside the approved range are handled by the manufacturer’s own quality system.
Define batch by time and a fixed process production rate has to be established first, because time only means something if the flow is controlled.
| Element | What the approvals show |
| Unit actually used | Mass |
| Products defining batch by time | None among the named products |
| Batch size as a range | Permitted |
| Fixed rate requirement | At least one product had to fix a continuous production rate |
| Management of in range variation | The manufacturer’s quality system |
Every approved product in this set defines batch by mass, not by time. Yet at least one of them, Trikafta, was still required to define a fixed continuous production rate so a regulator could assess process robustness. A mass based definition does not get you out of proving that the process runs at a controlled rate. That gap is the most common place where a first submission gets challenged.
Process validation in continuous manufacturing: three commercial batches are not compulsory
Validation requirements for continuous processes look broadly like those for batch processes. The route to satisfying them does not. A continuous process can lean on prior manufacturing experience, and commercial scale batches can be combined with development and clinical batch data. Three consecutive commercial scale batches are not a hard requirement.
The reviewer’s job is to judge whether existing development data, the proposed control strategy and batch analysis from commercial scale runs fully support the design space you claim.
| Approach | Status | Observed example |
| Three consecutive commercial batches | Accepted, not mandatory | Not the only route used in this set |
| Pooled development, clinical and commercial data | Accepted | Common across the approvals |
| Validation at commercial scale within a test programme | Accepted | Six batches validated, three at 30 kg and three at 40 kg, with reports submitted for three of the 40 kg batches |
For Symdeko, validation at commercial scale covered six batches split between 30 kg and 40 kg, while the submission provided actual validation reports for three of the 40 kg batches. That is the shape of the argument. A larger programme ran, and a subset went in to support the conclusion. The data set carried the case, not the batch count.
Technology transfer in continuous manufacturing and cleaning validation
Technology transfer is where a modular design pays you back. Where a second site uses exactly the same continuous equipment as the first, the review can focus on whether the reduced transfer package supports comparability, including confirmation data for the continuous equipment at each site. That is the Verzenio pattern. Identical equipment, identical layout, identical instruments, identical automation, so the transfer argument collapses into a qualification exercise.
Cleaning validation runs the other direction. Continuous processes are cleaned with the same agents, the same procedures, the same analytical methods and the same validation protocol as batch processes. Nothing in continuous operation changes the underlying science. What the review does look at is design: whether the line can be cleaned easily and whether parts can be swapped without breaking the validated state.
Process monitoring, PAT and the contingency plan
Process analytical technology is the normal monitoring route on a continuous line, because it measures product quality attributes in real time instead of inferring them later from a sample.
Two things get checked. Whether the applicant has put more than one control mechanism in place. And whether there is a workable contingency plan for the failure or unavailability of the primary analyzer. Daurismo is the reference case: when inline near infrared control was unavailable, for instance during a model update, stratified core sampling with an offline high performance liquid chromatography method took over, and layered control and alarms caught any shift in content so out of specification material was rejected.
| Control element | Expected backup or safeguard |
| Inline near infrared analyzer | Time based sampling plus an offline reference method |
| Multivariate model | A documented update path and revalidation trigger |
| Feeding | Continuous gravimetric monitoring against target mass flow |
| Residence time behaviour | An established residence time distribution |
| Alarm handling | Layered alarms and automatic diversion of affected material |
One analyzer with no fallback is what turns a strong submission into a deficiency letter. The reviewer is not asking whether your analyzer works. The reviewer is asking what the plant does on the day it does not.
PAT model robustness and lifecycle management
Process analytical technology measures the quality attributes of raw and intermediate materials and the process conditions in real time, then uses those measurements to design, analyse and control manufacturing so the finished product meets specification. Inline spectroscopic systems are the commonest tools, and near infrared dominates.
Review attention here is specific and high. The applicant should show that a multivariate model was built for monitoring, that the supporting data are sufficient, that robustness was verified, and that process model validation meets the applicable near infrared guidance for pharmaceutical use. A near infrared model directly determines whether product is accepted or rejected, which makes it a high risk element of the control strategy. Applicants are expected to describe how the model works and to manage its development, validation and maintenance across the whole lifecycle.
Which is why model documentation is so often the largest single section of a continuous manufacturing submission. Treat a model that decides release as part of the specification, not as an internal engineering tool.
Material traceability in pharmaceuticals and the product key concept
Batch manufacturing achieves traceability by recording the lot numbers of materials used. Continuous manufacturing cannot lean on that alone, because material does not sit in identified containers, and because a disturbance may touch only the material that passed a given point at a given moment.
So the review asks a different question. Can you identify the time window during which non conforming material was produced, link that window to material and to finished units, and confirm that when material fails specification, the finished product made from it is investigated as a whole?
| Aspect | Batch manufacturing | Continuous manufacturing |
| Primary record | Input lot numbers | Time stamps or product keys |
| Scope of a failure | The entire lot | The interval that produced out of specification material |
| Corrective action | Reject the lot | Divert material carrying the affected key |
| Reviewer’s question | Which lots used this input? | Which finished units came out during the bad interval? |
The Trikafta review illustrates this best. The agency placed substantial weight on material tracking and accepted the product key concept, under which material is tracked through the process and non conforming material and finished product are diverted. Two conditions made it acceptable: the tracking concept was described clearly, and the diversion method was validated.
The counterintuitive finding: less end product testing, more model scrutiny
You would expect continuous manufacturing to lighten the regulatory load, given that the process throws off far more data than batch manufacturing ever could. The approval record says otherwise.
Scrutiny migrates. Finished product testing gets lighter, because real time release replaces much of it. The freed attention goes somewhere else: to the multivariate model that decides acceptance and rejection, to the contingency plan for when that model is unavailable, and to the traceability mechanism that determines which units a deviation actually touches. Those are three things a batch manufacturer rarely has to defend in detail.
Read the sixteen approvals as a relocation of requirements rather than a relaxation of them. The evidence bar does not drop. It moves from the end of the line to the middle of it.
What this means in practice
For regulators building or extending a review framework:
- Treat early engagement as part of the technical process, not a courtesy. Sponsors who discussed plans and models before filing adjusted their submissions and avoided later deficiencies.
- Ask for the batch definition rationale in writing. Find out whether a range is claimed and whether a fixed production rate has been established.
- Do not require three commercial scale batches by default. Ask whether pooled development, clinical and commercial data support the claimed design space.
- Expect a defined trigger for model revalidation. Process models get updated as more data arrive, and a model used to determine a quality attribute should be treated as a reportable change.
- Require a named alternative for when inline measurement is unavailable, and check that it has been qualified.
- Accept simplified technology transfer only where equipment, layout, instruments and automation are genuinely identical.
- Assess real time release on its merits, and require a viable alternative where the release control strategy cannot be fully supported.
For manufacturers planning a continuous line:
- Settle the batch definition before designing the control strategy. It constrains everything downstream.
- Design for replication, not for a single site. Two identical lines turn technology transfer from a scientific argument into a qualification exercise.
- Build the contingency plan alongside the primary control loop. It is a standard deficiency item.
- Treat the process model as a registered element with a lifecycle, not as an internal engineering tool.
- Pick the first product deliberately. A mature product with a mechanically simple route and real market demand converts more easily than a novel product with a difficult formulation.
- Validate the traceability mechanism, including diversion, before you file.
Limitations
This analysis is bounded by what has been described publicly. Seven of the nine approved products have enough detail available to examine their process routes. Two are counted in the totals but not individually characterised.
The approval counts run to the end of 2021 and do not capture submissions filed or cleared afterwards. Read the totals as a historical record, not a current census.
The review questions listed here come from documented experience rather than from a published, universally applicable checklist. Agencies weight them differently, and a specific submission can turn on a formulation detail that no general framework captures.
Technical detail also varies a lot between the named cases. Process validation, traceability and model management are better documented for some products than for others, so the examples cited are the clearest available illustrations of each pattern rather than a uniform data set.
Bottom line
Continuous manufacturing of pharmaceuticals is past the proof of concept stage. Nine products and sixteen approvals across four agencies establish that the technology can be reviewed and approved on its merits, and that small molecule oral solid dosage forms dominate the list so far.
Equipment was never the bottleneck. What held filings up was the paperwork you have to rewrite once a process stops having a beginning and an end: what a batch is, what evidence validates it, how a second site is proven equivalent, and how a plant finds and removes the material produced during a bad interval.
Regulators and manufacturers preparing for ICH Q13 should start from those four questions. Everything else follows.
FAQ
What is continuous manufacturing in pharmaceuticals?
Continuous manufacturing of pharmaceuticals links unit operations so that material flows through them at a controlled rate instead of being charged and discharged in discrete lots. Quality is measured inline while the material moves, using process analytical technology, rather than by testing a finished lot. Scale comes from running longer at a fixed rate rather than from building larger vessels.
How many continuous manufacturing drug products have been approved?
Nine products held sixteen approval numbers across four agencies by the end of 2021, running from the first approval in 2015. The distribution was seven approvals at the FDA, six at the EMA, one at the MHRA and two at the PMDA. All known approvals covered oral solid dosage forms. Four sponsoring groups accounted for every product.
Which drug was the first continuous manufacturing product approved?
The first approval was granted in July 2015 for a cystic fibrosis treatment produced on a fully integrated continuous platform. Raw powder was fed into the system through an intermediate vessel, after which dry granulation, wet granulation and coating all ran continuously. The sponsor later built three sites on the same route at three different levels of automation maturity.
Does continuous manufacturing need three commercial validation batches?
No. Validation requirements are broadly similar to batch processes, but three consecutive commercial scale batches are not mandatory. Development, clinical and commercial data can be combined to support the claimed design space. One approved product validated six commercial scale batches, three at 30 kg and three at 40 kg, and submitted reports for three of the 40 kg batches.
How is a batch defined in continuous manufacturing?
Guidance allows a batch to be defined by production time or by material mass, and allows batch size to be a range. Every product in this approved set defines batch by mass. Even so, at least one product was still required to establish a fixed continuous production rate, because a mass based definition does not by itself prove that the process runs at a controlled rate.
What is real time release testing?
Real time release replaces finished product testing with in process measurement, allowing a batch to be released on the basis of data generated during manufacture rather than on testing of the final lot. One approved site supported it by integrating the whole line from individual material inputs through to a finished film coated tablet. The approach has to be justified for each product.
What is a product key in continuous manufacturing?
A product key is a tracking concept that links material to the interval during which it was processed. When an in process control result falls outside acceptable limits, material carrying the affected key is diverted out of the process. This gives traceability when material cannot be identified by lot number in a vessel. One approval relied on this concept with a validated diversion method.
What does PAT mean and why does it matter for approval?
PAT, or process analytical technology, measures the quality attributes of raw and intermediate materials and the process conditions in real time, then uses those measurements to control manufacturing. It matters because it carries the control burden that finished product testing used to carry. Near infrared spectroscopy is the commonest tool. Reviewers examine whether the model was validated and how it will be maintained.
Can an already marketed batch product be changed to continuous manufacturing?
Yes. The first such change was approved in 2016 for an HIV product on an integrated continuous direct compression platform. The sponsor cited three reasons for the choice: direct compression is mechanically simple, the product and its process were mature, and the indication had large demand. The existing batch data set became part of the evidence supporting the continuous design space.
Is cleaning validation different for continuous manufacturing?
No. Continuous processes use the same cleaning agents, procedures, analytical methods and validation protocols as batch processes. What the review examines instead is equipment design: whether the line can be cleaned easily and whether parts can be replaced or changed out without compromising the validated state. This is why modular and easily reconfigurable designs are favoured.
Why have most continuous manufacturing approvals been oral solid dosage forms?
Oral solid dosage forms combine a comparatively simple, stable process route with mature continuous equipment and available inline analytical support. Three routes account for every approved product: continuous wet granulation, continuous dry granulation and continuous direct compression. Products with more complex formulation behaviour carry higher development risk, which reduces the incentive to convert.
What should be in a technology transfer package when two sites use identical equipment?
Where a second site uses exactly the same continuous equipment as the first, the review can focus on whether the reduced package supports comparability. That means equipment qualification data and confirmation data for the continuous line at each production site, rather than a full re-establishment of the design space. This only works when equipment, layout, instruments and automation are genuinely identical.

Comments are closed